Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead Sciences GILD revealed 12 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 58% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $678,782, and 4 were calls, valued at $165,912.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $62.5 to $80.0 for Gilead Sciences over the recent three months.
Analyzing Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Gilead Sciences's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Gilead Sciences's whale activity within a strike price range from $62.5 to $80.0 in the last 30 days.
Gilead Sciences Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| GILD | PUT | SWEEP | BEARISH | 01/17/25 | $62.50 | $179.5K | 1.0K | 156 |
| GILD | PUT | SWEEP | BULLISH | 01/17/25 | $80.00 | $130.8K | 1.9K | 1.0K |
| GILD | PUT | SWEEP | BEARISH | 01/17/25 | $80.00 | $94.9K | 1.9K | 0 |
| GILD | PUT | SWEEP | BEARISH | 01/17/25 | $80.00 | $88.9K | 1.9K | 197 |
| GILD | PUT | SWEEP | BULLISH | 01/17/25 | $80.00 | $64.3K | 1.9K | 858 |
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
In light of the recent options history for Gilead Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Where Is Gilead Sciences Standing Right Now?
- Currently trading with a volume of 1,567,555, the GILD's price is up by 0.47%, now at $75.07.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 78 days.
Expert Opinions on Gilead Sciences
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $76.0.
- An analyst from RBC Capital persists with their Sector Perform rating on Gilead Sciences, maintaining a target price of $77.
- Reflecting concerns, an analyst from Deutsche Bank lowers its rating to Hold with a new price target of $75.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Gilead Sciences with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
